Sandra R Chaplan

US Patent:

7195879, Mar 27, 2007

Filed:

Apr 12, 2002

Appl. No.:

10/121759

Inventors:

Adrienne Dubin - San Diego CA, US
Sandra Chaplan - San Diego CA, US
Sean Brown - Encinitas CA, US
Edward Kaftan - Mount Prospect IL, US

Assignee:

Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ

International Classification:

G01N 33/53
C12N 5/00
C07D 239/00
C07C 69/00

US Classification:

435 71, 435375, 544247, 560 3

Abstract:

The present invention provides methods to manipulate differentiation of a neuroblastoma cell line (IMR-32) such that predominant Naexpression is either Na1. 3 in IMR-32 cells exposed to retinoic acid or Na1. 7 in cells grown under non-differentiating conditions. The cells of the present invention are useful for the discovery of new compounds that modulate the function of either Na1. 3 and/or Na1. 7.

US Patent:

20030022812, Jan 30, 2003

Filed:

May 30, 2002

Appl. No.:

10/158684

Inventors:

Sandra Chaplan - San Diego CA, US
Adrienne Dubin - San Diego CA, US
Doo Lee - Cardiff CA, US
Changlu Liu - San Diego CA, US

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

Markedly enhanced activity of pacemaker (hyperpolarization-activated, cation-nonselective, HCN) ion channels governs spontaneous firing in sensory cells of allodynic rats. An HCN ion channel specific blocker, ZD7288, dose-dependently and completely suppresses allodynia. Nerve injury increases the population of large DRG neurons expressing a high density of Iand modulates HCN mRNA expression. New methods of treating pain by targeting HCN pacemaker channels are developed. In addition, new methods for identifying compositions useful for treating pain are disclosed.

US Patent:

20030022813, Jan 30, 2003

Filed:

May 30, 2002

Appl. No.:

10/158711

Inventors:

Sandra Chaplan - San Diego CA, US
Adrienne Dubin - San Diego CA, US
Hong-Qing Guo - San Diego CA, US
Doo Lee - Cardiff CA, US
Changlu Liu - San Diego CA, US
Lin Luo - La Jolla CA, US
Sean Brown - Encinitas CA, US

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

Markedly enhanced activity of pacemaker (hyperpolarization-activated, cation-nonselective, HCN) ion channels governs spontaneous firing in sensory cells of allodynic rats. An HCN ion channel specific blocker, ZD7288, dose-dependently and completely suppresses allodynia. Nerve injury increases the population of large DRG neurons expressing a high density of Iand modulates HCN mRNA expression. New methods of treating pain by targeting HCN pacemaker channels are developed. In addition, new methods for identifying compositions useful for treating pain are disclosed.

US Patent:

20050250090, Nov 10, 2005

Filed:

Oct 28, 2004

Appl. No.:

10/975798

Inventors:

Edward Kaftan - Pennington NJ, US
Adrienne Dubin - San Diego CA, US
Sandra Chaplan - San Diego CA, US

International Classification:

C12Q001/00
C12Q001/68

US Classification:

435004000, 435006000

Abstract:

The invention provides methods including steps of: providing cells capable of expressing SK2; contacting the cells with a test molecule; obtaining information indicative of cellular SK2 expression to obtain an SK2 Expression Value; comparing the SK2 Expression Value with a control SK2 Expression Value; and identifying a test molecule that causes the cells to display an SK2 Expression Value that is different from the control SK2 Expression Value. Also provided are methods including steps of: providing a sample comprising an SK2 channel; contacting the sample with a test molecule; obtaining information indicative of SK2 channel activity in the sample to obtain an SK2 Channel Activity Value; comparing the SK2 Channel Activity Value with a control Channel Activity Value; and identifying a test molecule that causes the SK2 Channel Activity Value to be different from the control Channel Activity Value. Methods of identifying a molecule useful for treating neuropathic pain are also described.

US Patent:

20060257484, Nov 16, 2006

Filed:

Apr 13, 2006

Appl. No.:

11/404293

Inventors:

Stephen Hwang - Palo Alto CA, US
Sandra Chaplan - San Diego CA, US
Dong Yan - Cupertino CA, US
Patrick Wong - Burlingame CA, US
David Abraham - Menlo Park CA, US

International Classification:

A61K 31/195
A61K 31/137
A61K 9/24

US Classification:

424473000, 514561000, 514650000

Abstract:

Disclosed are substances, compositions, dosage forms and methods that comprise tramadol and substances that comprise gabapentin.

US Patent:

20080268439, Oct 30, 2008

Filed:

Apr 25, 2007

Appl. No.:

11/739789

Inventors:

Edward Kaftan - Pennington NJ, US
Adrienne Elizabeth Dubin - San Diego CA, US
Sandra R. Chaplan - San Diego CA, US

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435 6, 435 71

Abstract:

The invention provides methods including steps of: providing cells capable of expressing SK2; contacting the cells with a test molecule; obtaining information indicative of cellular SK2 expression to obtain an SK2 Expression Value; comparing the SK2 Expression Value with a control SK2 Expression Value; and identifying a test molecule that causes the cells to display an SK2 Expression Value that is different from the control SK2 Expression Value. Also provided are methods including steps of: providing a sample comprising an SK2 channel; contacting the sample with a test molecule; obtaining information indicative of SK2 channel activity in the sample to obtain an SK2 Channel Activity Value; comparing the SK2 Channel Activity Value with a control Channel Activity Value; and identifying a test molecule that causes the SK2 Channel Activity Value to be different from the control Channel Activity Value. Methods of identifying a molecule useful for treating neuropathic pain are also described.

US Patent:

58497374, Dec 15, 1998

Filed:

Apr 14, 1995

Appl. No.:

8/422377

Inventors:

Sandra Reading Chaplan - San Diego CA
Flemming Winther Bach - Aarhus, DK
Tony Lee Yaksh - San Diego CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31535
A61K 3116

US Classification:

5142388

Abstract:

Compositions and methods for alleviating pain (in particular, neuropathic pain) in a mammalian patient, wherein an effective amount of a physiologically-acceptable salt of a compound of the general formula ##STR1## wherein each of R. sup. 1, R. sup. 2 and R. sup. 3 is independently selected from the group consisting of hydrogen, hydroxyl, acyl, alkoxyl, alkyl, aryl, alkylaryl, arylalkyl, hydroxyalkyl, hydroxyaryl, alkoxyalkyl, alkoxyaryl and NR. sup. 8 R. sup. 9, in which each of R. sup. 8 and R. sup. 9 is independently selected from the group consisting of hydrogen, alkyl, aryl, acyl, alkylaryl, arylalkyl, hydroxyalkyl, hydroxyaryl, alkoxyalkyl and alkoxyaryl, with the proviso that at least one of R. sup. 1, R. sup. 2 and R. sup. 3 is hydroxyl; each of R. sup. 4 and R. sup. 5 is independently selected from the group consisting of hydrogen, halogen and lower alkyl; A is --C(. dbd.

US Patent:

6166085, Dec 26, 2000

Filed:

Sep 13, 1996

Appl. No.:

8/713339

Inventors:

Sandra Reading Chaplan - San Diego CA
Flemming Winther Bach - Aarhus, DK
Tony Lee Yaksh - San Diego CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 3152

US Classification:

514626

Abstract:

The invention relates to methods of producing analgesia, particularly in the treatment-of-acute and persistent pain and neuropathic pain. The compound 2(ethylamino)-N-(3-hydroxy-2,6-dimethylphenyl) acetamide, or 3-hydroxymonoethylglycinexylidide (3-hydroxy MEGX), is shown to provide analgesia in settings of acute, persistent and neuropathic pain.